The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor
Abstract
BACKGROUND: Statins (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] reductase inhibitors) have been used for a decade to lower low-density lipoprotein (LDL) cholesterol levels and to improve cardiovascular disease and clinical outcomes. OBJECTIVE: To evaluate the safety profile of atorvastatin (Lipitor). METHODS: Data were pooled for 21 completed (2502 patients) and 23 ongoing (1769 patients) clinical trials of atorvastatin conducted in US and international community- and university-based research centers. In these trials, patients with lipid disorders received atorvastatin at dosages of 10 to 80 mg/d. The majority of patients had moderate to severe hypercholesterolemia and were treated from 4 weeks to more than 24 months. MAIN OUTCOME MEASURES: Transaminase and creatine phosphokinase levels and adverse events were recorded. RESULTS: Atorvastatin was well tolerated; fewer than 2% of the atorvastatin-treated patients withdrew due to drug-attributable adverse events. The overall adverse event profile for atorvastatin was similar to that observed with other statins. The most common adverse events with atorvastatin as well as with other statins tested were constipation, flatulence, dyspepsia, and abdominal pain. Approximately 5% of atorvastatin-treated patients had serious adverse events; only 2 of these events were possibly associated with treatment. Thirty patients (0.7%) had confirmed transaminase elevations greater than 3 times the upper limit of the normal range. Most elevations occurred within 16 weeks of beginning treatment. No patients had a conclusive characterization of drug-induced myopathy. CONCLUSIONS: The safety profile of atorvastatin was consistent with that of all statins tested and was similar to that seen in all compounds of this class.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEECH, A., COLLINS, R., MACMAHON, S., ARMITAGE, J., LAWSON, A., WALLENDSZUS, K., FATEMIAN, M., KEARNEY, E., LYON, V., MINDELL, J., et al. (1994) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a060485 · Cited by 90
Cited by
Simić, S., Zukić, E., Schmermund, L., Faber, K., Winkler, C. K., & Kroutil, W. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00574 · Cited by 264
Downs, J. R., Clearfield, M., Tyroler, H. A., Whitney, E. J., Kruyer, W., Langendorfer, A., Zagrebelsky, V., Weis, S., Shapiro, D. R., Beere, P. A., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01464-3 · Cited by 138
Lins, R. L., Matthys, K. E., Verpooten, G. A., Peeters, P. C., Dratwa, M., Stolear, J.-C., & Lameire, N. H. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg048 · Cited by 128
“In non-renal patients, atorvastatin 10–80 mguday was well tolerated in clinical trials of up to 2 years involving over 2500 patients [31].”
BackgroundHargreaves, I. P., Duncan, A. J., Heales, S. J. R., & Land, J. M. (2005) · Drug Safety · doi:10.2165/00002018-200528080-00002 · Cited by 91
Metadata
- Authors
- Black, D. M., Bakker-Arkema, R. G., & Nawrocki, J. W.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1998-03-23
- Volume
- 158
- Issue
- 6
- Pages
- 577
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2008690571
- Cited by
- 161
- References
- 1
- FWCI
- 14.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.